Even more skin in the game.

Cemiplimab (Libtayo) is a PD-1 inhibitor used for advanced cutaneous squamous cell carcinoma. This single arm phase 2 trial evaluated the benefit of neoadjuvant cemiplimab for patients with resectable stage II-IV cutaneous SCC. Cemiplimab was administered every 3 weeks for up to 4 cycles prior to surgery. Among 79 patients, the pathologic complete response rate was 51% with an additional 13% having a major pathologic response. With more data, cemiplimab will likely play an expanding role in the definitive management of resectable cutaneous SCC–especially in patients with high risk, large, or advanced tumors that may require extensive surgery. | Gross, N Engl J Med 2022


Popular Posts